type 1 diabetes/celiac disease immunotherapy(Colorado Institute For Drug, Device and Diagnostic Development)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nametype 1 diabetes/celiac disease immunotherapy(Colorado Institute For Drug, Device and Diagnostic Development)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin E2 inhibitors
TargetsProstaglandin E2
Therapy Area/IndicationsDiabetes Mellitus, Type 1Celiac Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesColorado Institute For Drug, Device & Diagnostic Development
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesColorado Institute For Drug, Device & Diagnostic Development
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1Celiac Disease

Other Information

ATC CodeN/A
Related LinksN/A